RE: RNS out! Further funding!1 Sep 2025 15:20
“These CLNs strengthen our balance sheet, extend our financial runway, and enable us to maintain momentum in the clinical development of HG-CT-1 for patients with relapsed or refractory acute myeloid leukemia."